Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05933434 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Allogenic Mesenchymal Stem Cell Intraarticular Injection for Knee Osteoarthritis Therapy

Study acronym: STEMJOINT
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Mar 2024 to Mar 7, 2024 · Eligibility criteria shortened, about 7 words · 1 morev3 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2024 to Mar 7, 2024
    • Eligibility criteria shortened, about 7 words
    • Secondary endpoints: 8 to 7

    See this version in full on ClinicalTrials.gov ↗

  2. Start date: Oct 2023 to Mar 2024v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I and II double blinded randomized clinical controlled trial investigates the safety and efficacy of intraarticular knee injection with allogenic adipose derived mesenchymal stem cells (AD-MSC), in patients suffering from mild-moderate knee osteoarthritis compared to placebo injection with saline.
Trial Details
NCT Number NCT05933434
Lead Sponsor Aarhus University Hospital
Conditions Knee Osteoarthritis
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov